Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.15947 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nerve Block Research in Diabetic Foot Ulcers: Concerns and Suggestions [Response to Letter].
J Pain Res
January 2025
Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Province, 530021, People's Republic of China.
Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy.
Int J Retina Vitreous
January 2025
Brazilian Diabetes Society, São Paulo, Brazil.
In the last months, conflicting evidence on a possible association between the use of semaglutide and incident nonarteritic anterior ischemic optic neuropathy (NAION) has emerged. A recently published study, which evaluated all patients with type 2 diabetes in Denmark, has shown with robustness that once-weekly semaglutide doubles the five-year risk of NAION. In this comment, the new evidence is discussed, along with practical implications for type 2 diabetes patients.
View Article and Find Full Text PDFComment on "Combined Autologous Breast Reconstruction and Gynecologic Procedures: Does Timing Affect Clinical and Patient-Reported Outcomes?".
J Surg Oncol
January 2025
Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Comment On: "Comparison of Reconstructive Techniques for Nonprimary Malignancies in the Proximal Humerus".
J Surg Oncol
January 2025
Rehabilitation Department, Haiyan Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, The People's Republic of China.
Comment on: "Effectiveness of Exosome Treatment in Androgenetic Alopecia: Outcomes of a Prospective Study".
Aesthetic Plast Surg
January 2025
Department of Rehabilitation Treatment, Jiangsu Rongjun Hospital, Wuxi, Jiangsu, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!